MedTrace Logo

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

NCT03697564 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-08-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.

Conditions

  • Pancreatic Cancer Stage IV

Interventions

DRUG

Gemcitabine

1000 mg/m2 IV on days 1, 8, and 15 Q4W

DRUG

Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]

480mg IV on Day 1 Q4W

DRUG

Cabiralizumab

4mg/kg IV on day 1 and 15 Q4W

Sponsors & Collaborators

  • Stand Up To Cancer

    collaborator OTHER

  • Lustgarten Foundation

    collaborator OTHER

  • Hitendra Patel

    lead OTHER

Principal Investigators

  • Hitendra Patel, MD · University of California, San Diego

  • Andrew Lowy, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2023-04-12
Completion
2023-07-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697564 on ClinicalTrials.gov